Breaking News, Collaborations & Alliances

AstraZeneca, Ovid Therapeutics Partner Against Epilepsy

Transaction is the first business development activity that seeks to enhance Ovid’s pipeline of small-molecule and genetic CNS medicines.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ovid Therapeutics has entered into an exclusive license agreement with AstraZeneca for a library of early-stage small molecules targeting the KCC2 transporter, including lead candidate, OV350. The company seeks to optimize and accelerate development of these KCC2 transporter activators in epilepsies and potentially other neuropathic conditions.   “The KCC2 transporter is an exciting and novel target that we believe holds great promise in treating epilepsies,” said Jeremy Levin, CEO, Ovid. “The c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters